Interleukin‑22 promotes PD‑L1 expression via STAT3 in colon cancer cells

Xi,Xiangpeng; Hu,Rui; Wang,Qi; Xu,Kang; Yang,Hui; Cui,Zhonghui; Zhang,Yongbo; Teng,Mujian; Xia,Lijian; Chen,Jingbo; Liu,Yulin

doi:10.3892/ol.2021.12977

Interleukin‑22 promotes PD‑L1 expression via STAT3 in colon cancer cells

Authors:
- Xiangpeng Xi
- Rui Hu
- Qi Wang
- Kang Xu
- Hui Yang
- Zhonghui Cui
- Yongbo Zhang
- Mujian Teng
- Lijian Xia
- Jingbo Chen
- Yulin Liu
View Affiliations

Affiliations: Department of General Surgery, The First Affiliated Hospital of Shandong First Medical University, Jinan, Shandong 250014, P.R. China, Center for Reproductive Medicine, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250013, P.R. China, Department of Pharmacy, The Fifth People's Hospital of Jinan, Jinan, Shandong 250022, P.R. China
Published online on: August 8, 2021 https://doi.org/10.3892/ol.2021.12977
Article Number: 716

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Blocking the expression of programmed cell death ligand 1 (PD‑L1) is a promising approach for the treatment of colon cancer. The binding of PD‑L1 to its receptor programmed cell death 1 (PD‑1) on immune cells leads to the apoptosis of activated T cells and causes immune escape. However, there is a limited number of patients with colon cancer that can benefit from the inhibition of PD‑L1, and the regulation of PD‑L1 expression is poorly understood in colon cancer. The present study demonstrated that interleukin‑22 (IL‑22) and PD‑L1 were upregulated in colon cancer tissues and there was a positive correlation between IL‑22 expression and PD‑L1 expression. In the present study, exogenous IL‑22 was found to upregulate PD‑L1 expression via the signal transducer and activator of transcription 3 signaling pathway in human colon cancer cells (DLD‑1 and primary colon cancer cells). The results of the present study revealed a novel regulatory mechanism of PD‑L1 expression in colon cancer, which provides a theoretical basis for decreasing the immune tolerance of colon cancer via IL‑22 overexpression.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Body A, Prenen H, Latham S, Lam M, Tipping-Smith S, Raghunath A and Segelov E: The Role of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer. Cancer Manag Res. 13:2567–2579. 2021. View Article : Google Scholar : PubMed/NCBI
3	Yaghoubi N, Soltani A, Ghazvini K, Hassanian SM and Hashemy SI: PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer. Biomed Pharmacother. 110:312–318. 2019. View Article : Google Scholar : PubMed/NCBI
4	Sun C, Mezzadra R and Schumacher TN: Regulation and function of the PD-L1 checkpoint. Immunity. 48:434–452. 2018. View Article : Google Scholar : PubMed/NCBI
5	Juneja VR, McGuire KA, Manguso RT, LaFleur MW, Collins N, Haining WN, Freeman GJ and Sharpe AH: PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med. 214:895–904. 2017. View Article : Google Scholar : PubMed/NCBI
6	Masugi Y, Nishihara R, Yang J, Mima K, da Silva A, Shi Y, Inamura K, Cao Y, Song M, Nowak JA, et al: Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut. 66:1463–1473. 2017. View Article : Google Scholar : PubMed/NCBI
7	Pyo JS, Ko SH, Ko YS and Kim NY: Clinicopathological significance of PD-L1 expression in colorectal cancer: Impact of PD-L1 expression on pFOXO1 expression. Pathol Res Pract. 216:1527642020. View Article : Google Scholar : PubMed/NCBI
8	Li Y, He M, Zhou Y, Yang C, Wei S, Bian X, Christopher O and Xie L: The prognostic and clinicopathological roles of PD-L1 expression in colorectal cancer: A systematic review and meta-analysis. Front Pharmacol. 10:1392019. View Article : Google Scholar : PubMed/NCBI
9	Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, et al: Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study. Lancet Oncol. 18:1182–1191. 2017. View Article : Google Scholar : PubMed/NCBI
10	Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, Kim GP, Yothers G, Allegra C, Moore MJ, et al: DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst. 103:863–875. 2011. View Article : Google Scholar : PubMed/NCBI
11	Wolk K, Witte E, Witte K, Warszawska K and Sabat R: Biology of interleukin-22. Semin Immunopathol. 32:17–31. 2010. View Article : Google Scholar : PubMed/NCBI
12	Jiang R, Wang H, Deng L, Hou J, Shi R, Yao M, Gao Y, Yao A, Wang X, Yu L and Sun B: IL-22 is related to development of human colon cancer by activation of STAT3. BMC Cancer. 13:592013. View Article : Google Scholar : PubMed/NCBI
13	Sun D, Lin Y, Hong J, Chen H, Nagarsheth N, Peng D, Wei S, Huang E, Fang J, Kryczek I and Zou W: Th22 cells control colon tumorigenesis through STAT3 and Polycomb Repression complex 2 signaling. Oncoimmunology. 5:e10827042015. View Article : Google Scholar : PubMed/NCBI
14	Kryczek I, Lin Y, Nagarsheth N, Peng D, Zhao L, Zhao E, Vatan L, Szeliga W, Dou Y, Owens S, et al: IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L. Immunity. 40:772–784. 2014. View Article : Google Scholar : PubMed/NCBI
15	Liu Y, Xiang F, Huang Y, Shi L, Hu C, Yang Y, Wang D, He N, Tao K, Wu K and Wang G: Interleukin-22 promotes aerobic glycolysis associated with tumor progression via targeting hexokinase-2 in human colon cancer cells. Oncotarget. 8:25372–25383. 2017. View Article : Google Scholar : PubMed/NCBI
16	Chen S, Crabill GA, Pritchard TS, McMiller TL, Wei P, Pardoll DM, Pan F and Topalian SL: Mechanisms regulating PD-L1 expression on tumor and immune cells. J Immunother Cancer. 7:3052019. View Article : Google Scholar : PubMed/NCBI
17	Seki N, Kan-O K, Matsumoto K, Fukuyama S, Hamano S, Tonai K, Ota K, Inoue H and Nakanishi Y: Interleukin-22 attenuates double-stranded RNA-induced upregulation of PD-L1 in airway epithelial cells via a STAT3-dependent mechanism. Biochem Biophys Res Comm. 494:242–248. 2017. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Eppihimer MJ, Gunn J, Freeman GJ, Greenfield EA, Chernova T, Erickson J and Leonard JP: Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation. 9:133–145. 2002. View Article : Google Scholar : PubMed/NCBI
20	Wang X, Yang L, Huang F, Zhang Q, Liu S, Ma L and You Z: Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells. Immunol Lett. 184:7–14. 2017. View Article : Google Scholar : PubMed/NCBI
21	Qian J, Wang C, Wang B, Yang J, Wang Y, Luo F, Xu J, Zhao C, Liu R and Chu Y: The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: Hints for glioma anti-PD-1/PD-L1 therapy. J Neuroinflammation. 15:2902018. View Article : Google Scholar : PubMed/NCBI
22	Chan LC, Li CW, Xia W, Hsu JM, Lee HH, Cha JH, Wang HL, Yang WH, Yen EY, Chang WC, et al: IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. J Clin Invest. 129:3324–3338. 2019. View Article : Google Scholar : PubMed/NCBI
23	Hernandez P, Gronke K and Diefenbach A: A catch-22: Interleukin-22 and cancer. Eur J Immunol. 48:15–31. 2018. View Article : Google Scholar : PubMed/NCBI
24	Wolk K, Witte E, Wallace E, Döcke WD, Kunz S, Asadullah K, Volk HD, Sterry W and Sabat R: IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: A potential role in psoriasis. Eur J Immunol. 36:1309–1323. 2006. View Article : Google Scholar : PubMed/NCBI
25	Eyerich S, Eyerich K, Pennino D, Carbone T, Nasorri F, Pallotta S, Cianfarani F, Odorisio T, Traidl-Hoffmann C, Behrendt H, et al: Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest. 119:3573–3585. 2009.PubMed/NCBI
26	Galoczova M, Coates P and Vojtesek B: STAT3, stem cells, cancer stem cells and p63. Cell Mol Biol Lett. 23:122018. View Article : Google Scholar : PubMed/NCBI
27	Yu H, Lee H, Herrmann A, Buettner R and Jove R: Revisiting STAT3 signalling in cancer: New and unexpected biological functions. Nat Rev Cancer. 14:736–746. 2014. View Article : Google Scholar : PubMed/NCBI
28	Fathi N, Rashidi G, Khodadadi A, Shahi S and Sharifi S: STAT3 and apoptosis challenges in cancer. Int J Biol Macromol. 117:993–1001. 2018. View Article : Google Scholar : PubMed/NCBI
29	Li P, Huang T and Zou Q: FGFR2 promotes expression of PD-L1 in colorectal cancer via the JAK/STAT3 signaling pathway. J Immunol. 202:3065–3075. 2019. View Article : Google Scholar : PubMed/NCBI
30	Jahangiri A and Dadmanesh M: STAT3 inhibition reduced PD-L1 expression and enhanced antitumor immune responses. J Cell Physiol. 235:9457–9463. 2020. View Article : Google Scholar : PubMed/NCBI